CenterBook Partners LP Acquires New Position in Repligen Corporation $RGEN

CenterBook Partners LP acquired a new stake in Repligen Corporation (NASDAQ:RGEN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 17,672 shares of the biotechnology company’s stock, valued at approximately $2,362,000.

Several other institutional investors and hedge funds also recently made changes to their positions in RGEN. Hantz Financial Services Inc. boosted its position in shares of Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares during the last quarter. CWM LLC increased its holdings in Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares during the last quarter. Center for Financial Planning Inc. lifted its stake in Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 126 shares during the period. Trust Co. of Vermont bought a new position in Repligen during the third quarter worth about $67,000. Finally, Wilmington Savings Fund Society FSB boosted its holdings in Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after buying an additional 495 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of analyst reports. UBS Group increased their price target on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Canaccord Genuity Group boosted their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. Finally, Barclays upped their price objective on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $177.92.

Insider Transactions at Repligen

In other news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. This trade represents a 0.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Repligen Stock Performance

RGEN opened at $137.22 on Friday. The company has a market capitalization of $7.72 billion, a price-to-earnings ratio of 6,864.43, a P/E/G ratio of 2.52 and a beta of 1.13. The business’s 50-day moving average price is $157.24 and its two-hundred day moving average price is $145.97. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.